AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2666559 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacological therapy (started after 1 year for G1)
Number of subjects: 400
Study 2666559 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacological therapy (used from the beginning for G2)
Number of subjects: 400
Study 2666559 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacological therapy (for both groups)
Number of subjects: 400
Study 371032 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol
Number of subjects: 0
Study 371032 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0
Study 371032 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbitone
Number of subjects: 0
Study 30391434 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin plus epinephrine (IE)
Number of subjects: 1158
Study 30391434 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin plus saline (IS)
Number of subjects: 1158
Study 28865550 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-lapse system (TLS)
Number of subjects: 378
Study 25838254 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivantinib
Number of subjects: 0
Study 25838254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24142473 — intervention group
Group type: EXPERIMENTAL
Intervention: Besifloxacin ophthalmic suspension 0.6 %
Number of subjects: 518
Study 24142473 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 518
Study 24142473 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 518
Study 21132438 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (CWI)
Number of subjects: 41
Study 21132438 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast Water Therapy (CWT)
Number of subjects: 41
Study 21132438 — intervention group
Group type: COMPARATOR
Intervention: Passive Recovery (PAS)
Number of subjects: 41
Study 21132438 — intervention group
Group type: COMPARATOR
Intervention: Temperate Water Immersion (TWI)
Number of subjects: 41
Study 19860495 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant orthopedics (IO+) until surgical closure of the soft palate at approximately 52 weeks
Number of subjects: 54
Study 19860495 — intervention group
Group type: COMPARATOR
Intervention: No intervention (IO-)
Number of subjects: 54
Study 16770975 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 50
Study 16770975 — intervention group
Group type: COMPARATOR
Intervention: Simulated acupuncture (Control)
Number of subjects: 50
Study 16237983 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular irradiation therapy
Number of subjects: 15
Study 16237983 — intervention group
Group type: COMPARATOR
Intervention: Nonradiation (stenting only)
Number of subjects: 15
Study 11795586 — intervention group
Group type: EXPERIMENTAL
Intervention: The Coalition for Youth Quality of Life Project (ecological and participatory approach)
Number of subjects: 791
Study 9428121 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 grams a day of oral acyclovir for 16 weeks after transplantation
Number of subjects: 73
Study 9428121 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 73
Study 8515787 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of vesnarinone per day
Number of subjects: 477
Study 8515787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 477
Study 8515787 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg of vesnarinone per day
Number of subjects: 477
Study 2893583 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 220
Study 2893583 — intervention group
Group type: COMPARATOR
Intervention: Fresh frozen plasma (FFP)
Number of subjects: 220
Study 2893583 — intervention group
Group type: COMPARATOR
Intervention: Diluted albumin
Number of subjects: 220
Study 31094640 — intervention group
Group type: COMPARATOR
Intervention: Sham KT + BE
Number of subjects: 48
Study 31094640 — intervention group
Group type: EXPERIMENTAL
Intervention: KT + BE
Number of subjects: 48
Study 31094640 — intervention group
Group type: EXPERIMENTAL
Intervention: KT in isolation
Number of subjects: 48
Study 31094640 — intervention group
Group type: COMPARATOR
Intervention: Sham KT
Number of subjects: 48
Study 31662037 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous and intra-arterial therapies
Number of subjects: 100
Study 31662037 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary prevention measures
Number of subjects: 100
Study 28101887 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 0
Study 28101887 — intervention group
Group type: COMPARATOR
Intervention: Abiraterone acetate (AA) with prednisone
Number of subjects: 0
Study 28101887 — intervention group
Group type: COMPARATOR
Intervention: Enzalutamide or AA
Number of subjects: 0
Study 26079223 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 g/d GAA
Number of subjects: 48
Study 26079223 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.4 g/d GAA
Number of subjects: 48
Study 26079223 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.8 g/d GAA
Number of subjects: 48
Study 26079223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 23511822 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI during an 8-minute auditory semantic decision task
Number of subjects: 35
Study 21650082 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of perindopril erbumine 4 mg
Number of subjects: 20
Study 21650082 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of perindopril erbumine 4 mg
Number of subjects: 20
Study 19167636 — intervention group
Group type: EXPERIMENTAL
Intervention: Cibenzoline (Cib, 70 mg)
Number of subjects: 68
Study 19167636 — intervention group
Group type: COMPARATOR
Intervention: Pilsicainide (Pil, 50 mg)
Number of subjects: 68
Study 16750796 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg twice daily
Number of subjects: 233
Study 16750796 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (including gabapentin, venlafaxine, amitriptyline)
Number of subjects: 233
Study 15187799 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-focused cognitive-behavioral therapy (TF-CBT)
Number of subjects: 229
Study 15187799 — intervention group
Group type: COMPARATOR
Intervention: Child-centered therapy
Number of subjects: 229
Study 11483229 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 25
Study 10806698 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (600 micrograms orally when peritoneum was incised)
Number of subjects: 182
Study 10806698 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (600 micrograms orally) and Oxytocin (20 IU injected into uterine muscle immediately after delivery)
Number of subjects: 182
Study 10806698 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin (20 IU injected into uterine muscle and 20 IU intravenous injection immediately after delivery)
Number of subjects: 182
Study 7827631 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic knee braces; 23 knee injuries in 21,640 exposures
Number of subjects: 8
Study 7827631 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic knee braces; 26 knee injuries in 19,484 exposures
Number of subjects: 8
Study 3137469 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC + ICRF‐187
Number of subjects: 92
Study 3137469 — intervention group
Group type: COMPARATOR
Intervention: FDC
Number of subjects: 92
Study 29528117 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (2 μg kg-1 min-1)
Number of subjects: 13
Study 29528117 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia (100% O2)
Number of subjects: 13
Study 29528117 — intervention group
Group type: COMPARATOR
Intervention: Control (i.v. saline)
Number of subjects: 13
Study 29528117 — intervention group
Group type: COMPARATOR
Intervention: Control (i.v. dopamine)
Number of subjects: 13
Study 29528117 — intervention group
Group type: COMPARATOR
Intervention: Control (hyperoxia)
Number of subjects: 13
Study 26951940 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 40‐mg modified‐release capsules
Number of subjects: 170
Study 26951940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 24721108 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based guided self-help intervention based on problem-solving therapy for glioma patients with depressive symptoms.
Number of subjects: 126
Study 24721108 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group for glioma patients.
Number of subjects: 126
Study 24721108 — intervention group
Group type: COMPARATOR
Intervention: Non-central nervous system malignancy control group (haematological cancer patients).
Number of subjects: 126
Study 24721108 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based guided self-help intervention.
Number of subjects: 126
Study 24721108 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group.
Number of subjects: 126
Study 24721108 — intervention group
Group type: COMPARATOR
Intervention: Non-central nervous system malignancy control group.
Number of subjects: 126
Study 23570677 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (8 g magnesium sulphate heptahydrate in 50 ml infusion over 30 minutes)
Number of subjects: 1676
Study 23570677 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic sodium chloride solution 0.9% in 50 ml infusion over 30 minutes)
Number of subjects: 1676
Study 20172643 — intervention group
Group type: EXPERIMENTAL
Intervention: Two simple questions assessing everyday activities and mental recovery
Number of subjects: 32
Study 20172643 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-Mental State Examination (MMSE)
Number of subjects: 32
Study 20172643 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Utilities Index Mark 3 (HUI3)
Number of subjects: 32
Study 18772586 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil-enriched spread
Number of subjects: 0
Study 18772586 — intervention group
Group type: COMPARATOR
Intervention: Control spread
Number of subjects: 0
Study 16616347 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication
Number of subjects: 72
Study 16616347 — intervention group
Group type: COMPARATOR
Intervention: Continued medical therapy (control group)
Number of subjects: 72
Study 12243220 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive problem-solving skills
Number of subjects: 32
Study 12243220 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtypes of problem-solving skills
Number of subjects: 32
Study 9539998 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic retinopathy
Number of subjects: 419
Study 9539998 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic neuropathy
Number of subjects: 419
Study 9539998 — intervention group
Group type: EXPERIMENTAL
Intervention: Microalbuminuria
Number of subjects: 419
Study 9539998 — intervention group
Group type: EXPERIMENTAL
Intervention: Overt albuminuria
Number of subjects: 419
Study 9539998 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing retinopathy stage
Number of subjects: 419
Study 9539998 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing UAE stage
Number of subjects: 419
Study 8024262 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 0
Study 8024262 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (low and medium doses)
Number of subjects: 0
Study 8024262 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose scopolamine
Number of subjects: 0
Study 2919766 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracaine 1% (hypobaric 0.25%)
Number of subjects: 30
Study 2919766 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% (hypobaric 0.25%)
Number of subjects: 30
Study 1056947 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly developed dental training simulator
Number of subjects: 30
Study 1056947 — intervention group
Group type: COMPARATOR
Intervention: Traditional training method (Control)
Number of subjects: 30
Study 30589502 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided sleeve height of 2 mm, 4 mm, 6 mm
Number of subjects: 0
Study 30589502 — intervention group
Group type: EXPERIMENTAL
Intervention: Drilling distance of 18 mm
Number of subjects: 0
Study 30589502 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided key height of 3 mm
Number of subjects: 0
Study 30589502 — intervention group
Group type: EXPERIMENTAL
Intervention: Total drilling distance below the guided sleeve
Number of subjects: 0
Study 30589502 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided key height above the sleeve
Number of subjects: 0
Study 28096208 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase administered at the CT scanner
Number of subjects: 350
Study 28096208 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient brought directly to CT on emergency medical services stretcher
Number of subjects: 350
Study 28096208 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient registered as unknown
Number of subjects: 350
Study 28096208 — intervention group
Group type: EXPERIMENTAL
Intervention: STAT stroke protocol implemented
Number of subjects: 350
Study 28096208 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke severity (NIHSS score 6-8)
Number of subjects: 350
Study 28096208 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke severity (NIHSS score >8)
Number of subjects: 350
Study 24187862 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzhengpaidu granule (FZPDG) for six months
Number of subjects: 34
Study 21376167 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenazopyridine hydrochloride
Number of subjects: 240
Study 21376167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 19660517 — intervention group
Group type: EXPERIMENTAL
Intervention: ARC-I (saliva contamination, blot-dried)
Number of subjects: 0
Study 19660517 — intervention group
Group type: EXPERIMENTAL
Intervention: ARC-II (saliva contamination, rinse, blot-dried)
Number of subjects: 0
Study 19660517 — intervention group
Group type: EXPERIMENTAL
Intervention: ARC-III (saliva contamination, rinse, re-etch, rinse, blot-dried)
Number of subjects: 0
Study 19660517 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-I (saliva contamination, dried)
Number of subjects: 0
Study 19660517 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-III (primer, saliva contamination, dried)
Number of subjects: 0
Study 19660517 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-IV (primer, saliva contamination, dried, primer re-applied)
Number of subjects: 0
Study 19660517 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-II (saliva contamination, rinse, dried)
Number of subjects: 0
Study 19660517 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-V (primer, saliva contamination, rinse, dried, primer re-applied)
Number of subjects: 0
Study 19660517 — intervention group
Group type: COMPARATOR
Intervention: ARC-control (uncontaminated)
Number of subjects: 0
Study 19660517 — intervention group
Group type: COMPARATOR
Intervention: PF-control (uncontaminated)
Number of subjects: 0
Study 17270614 — intervention group
Group type: EXPERIMENTAL
Intervention: Urethral botulinum A toxin (BoNT‐A) injection
Number of subjects: 27
Study 15520109 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) and supplemental iron therapy
Number of subjects: 172
Study 15520109 — intervention group
Group type: COMPARATOR
Intervention: Placebo/control with supplemental iron alone
Number of subjects: 172
Study 15520109 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo)
Number of subjects: 172
Study 11274622 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 40
Study 11274622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9488514 — intervention group
Group type: EXPERIMENTAL
Intervention: Omentoplasty (OP)
Number of subjects: 705
Study 9488514 — intervention group
Group type: COMPARATOR
Intervention: No Omentoplasty (NO)
Number of subjects: 705
Study 8043312 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa treated with lithium ion (40 +/- 5 ppm)
Number of subjects: 53
Study 8043312 — intervention group
Group type: COMPARATOR
Intervention: Control spa (no additional lithium ion, background levels of approximately 0.02 ppm)
Number of subjects: 53
Study 2197681 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine chewing gum
Number of subjects: 996
Study 2197681 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 996
Study 2197681 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for both interventions)
Number of subjects: 996
Study 1101130 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexivacaine 2%
Number of subjects: 0
Study 1101130 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine 2%
Number of subjects: 0
Study 1101130 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine 3%
Number of subjects: 0
Study 30634923 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuously supervised aerobic exercise training program (18 months, 3 days/week)
Number of subjects: 300
Study 30634923 — intervention group
Group type: COMPARATOR
Intervention: Behavioral counseling on physical activity and diet
Number of subjects: 300
Study 28218006 — intervention group
Group type: EXPERIMENTAL
Intervention: Red laser (660 nm) treatment with 4 j/cm² in TMJs and 8 j/cm² in muscles, applied in three sessions.
Number of subjects: 19
Study 28218006 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared laser (790 nm) treatment with 4 j/cm² in TMJs and 8 j/cm² in muscles, applied in three sessions.
Number of subjects: 19
Study 25708022 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg droxidopa
Number of subjects: 85
Study 25708022 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg droxidopa
Number of subjects: 85
Study 25708022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 23479675 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral shoulder position
Number of subjects: 362
Study 23479675 — intervention group
Group type: COMPARATOR
Intervention: Retracted shoulder position
Number of subjects: 362
Study 21632496 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated baseline white blood cell count (WBCc)
Number of subjects: 3193
Study 21632496 — intervention group
Group type: EXPERIMENTAL
Intervention: High WBCc (>11,000 per 1 mm³)
Number of subjects: 3193
Study 19940728 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminectomy bone chips mixed with bone marrow aspirate (BMA)
Number of subjects: 43
Study 19940728 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium sulfate pellets soaked in BMA
Number of subjects: 43
Study 19940728 — intervention group
Group type: COMPARATOR
Intervention: Autologous iliac crest bone graft (ICBG)
Number of subjects: 43
Study 16801582 — intervention group
Group type: EXPERIMENTAL
Intervention: High dairy intake (highest quintile)
Number of subjects: 37183
Study 16801582 — intervention group
Group type: EXPERIMENTAL
Intervention: Each serving-per-day increase in dairy intake
Number of subjects: 37183
Study 16801582 — intervention group
Group type: EXPERIMENTAL
Intervention: High low-fat dairy intake (highest quintile)
Number of subjects: 37183
Study 16801582 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy intake (overall)
Number of subjects: 37183
Study 16647363 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecture on obtaining informed consent
Number of subjects: 0
Study 16647363 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise training combined with consent training
Number of subjects: 0
Study 14657822 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk
Number of subjects: 13
Study 14657822 — intervention group
Group type: COMPARATOR
Intervention: Preterm infant formula
Number of subjects: 13
Study 10081530 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous interscalene brachial plexus block with bupivacaine (1.25 mg kg‐1 + 0.25 mg kg‐1 h‐1)
Number of subjects: 30
Study 10081530 — intervention group
Group type: COMPARATOR
Intervention: Morphine (5 mg i.m. and 2 mg i.v.)
Number of subjects: 30
Study 10081530 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia with morphine (bolus 1 mg)
Number of subjects: 30
Study 7553233 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical interferon-beta cream
Number of subjects: 35
Study 7553233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 2187327 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated sodium fluoride tablets and calcium supplements
Number of subjects: 101
Study 2187327 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated sodium fluoride tablets and calcium supplements with vitamin D
Number of subjects: 101
Study 2187327 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and sex-matched)
Number of subjects: 101
Study 41455 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline chloride (up to 20 g/day)
Number of subjects: 9
Study 31811360 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily oral iron therapy (60 mg elemental iron twice daily)
Number of subjects: 62
Study 31811360 — intervention group
Group type: COMPARATOR
Intervention: Alternate-day oral iron therapy (120 mg iron on alternate days)
Number of subjects: 62
Study 31206591 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal ropivacaine (Group IPLA)
Number of subjects: 40
Study 31206591 — intervention group
Group type: COMPARATOR
Intervention: Saline (Group P)
Number of subjects: 40
Study 28829766 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive intervention (chance to win a £50 shopping voucher for returning a consent form)
Number of subjects: 6
Study 28829766 — intervention group
Group type: COMPARATOR
Intervention: Standard invitation arm
Number of subjects: 6
Study 26132140 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulphate (50 mg/day)
Number of subjects: 120
Study 26132140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 23479454 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening Arm (SA) - PSA determination up to three times with a 4-year interval.
Number of subjects: 80144
Study 23479454 — intervention group
Group type: COMPARATOR
Intervention: Control Arm (CA) - Usual care.
Number of subjects: 80144
Study 21696889 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 200 μg/kg
Number of subjects: 217